ReviewCureus2026
A Narrative Review of the Potential Impact of Next-Generation Tobacco and Nicotine Products on Cardiovascular Health.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cigarette smoking is a cause of serious disease in smokers, including cardiovascular disease (CVD). The processes underpinning the development of CVD are well understood. These involve many cell types and cellular processes contributing to the development of atherosclerotic plaques in blood vessels, leading to impaired tissue oxygen supply and acute manifestations such as myocardial infarction and stroke. Cigarette smoke contains thousands of chemicals, some of which can be harmful to the cardiovascular system and may promote atherogenesis. In this narrative review, we assess the growing body of evidence concerning the potential cardiovascular health impact of next‑generation tobacco and nicotine product (NGP) use, including electronic vaping product (EVP), heated tobacco product (HTP) and oral nicotine pouch (ONP) use. Exclusive use of NGPs substantially reduces exposure to harmful toxicants compared with cigarette smoking. Regarding CVD risk, we determine that: (i) in vivo and in vitro
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.